» Articles » PMID: 28888813

Gender-specific Differences in Recurrence of Non-muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis

Overview
Journal Eur Urol Focus
Specialty Urology
Date 2017 Sep 11
PMID 28888813
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

Context: The incidence of urothelial carcinoma of the bladder (UCB) is lower in women; however, women tend to present with more advanced disease. To date, there is no quantitative synthesis of studies reporting gender-specific outcomes in non-muscle-invasive UCB.

Objective: To conduct a meta-analysis evaluating gender-specific differences in recurrence of non-muscle-invasive urinary bladder cancer (NMIBC).

Evidence Acquisition: An unrestricted systematic literature search of the MEDLINE, EMBASE, and Cochrane libraries was conducted. Studies evaluating the impact of gender on disease recurrence after local treatment of NMIBC using multivariable Cox proportional hazard models were included. Random effect meta-analysis, subgroup analyses, meta-influence, and cumulative meta-analyses were conducted. Publication bias was assessed via a funnel plot and Eggeŕs test.

Evidence Synthesis: Of 609 studies screened, 27 comprising 23 754 patients were included. Random effect meta-analyses indicated women at increased risk for UCB recurrence compared with men (hazard ratio [HR]=1.11, 95% confidence interval [CI]: 1.01-1.23, p=0.03). Subgroup analyses yielded estimates between HR=0.99 and HR=1.68. Gender-specific differences in UCB recurrence were most pronounced in studies administering exclusively bacillus Calmette-Guerin (BCG; HR=1.64, 95% CI: 1.13-2.39, p=0.01), especially in a long-term treatment regimen (HR=1.68, 95% CI: 1.32-2.15, p<0.001). Sensitivity analyses confirmed female patients at increased risk for UCB recurrence.

Conclusions: Women are at increased risk for disease recurrence after local treatment of NMIBC compared with male patients. Reduced effectiveness of BCG treatment might underlie this observation. Gender-specific differences were evident across various subgroups and proved robust upon sensitivity analyses.

Patient Summary: In this report, we combined several studies on gender-specific differences in relapse of superficial bladder cancer. Women were more likely to experience cancer relapse than men.

Citing Articles

Sex-specific differences in recurrence and progression following cytostatic intravesical chemotherapy for non-muscle invasive urothelial bladder cancer (NMIBC).

Schneidewind L, Kiss B, Neumann T, Kranz J, Zengerling F, Graf S J Cancer Res Clin Oncol. 2025; 151(2):59.

PMID: 39891792 PMC: 11787168. DOI: 10.1007/s00432-025-06108-x.


Stoma Acceptance Mediates Body Image Distress and Mental Health-Related Quality of Life: A Single-Center Study on Radical Cystectomy Patients with Ureterostomy.

Muzii B, Di Bello F, Colla Ruvolo C, Morra S, Polverino F, Pessolano C J Clin Med. 2025; 13(24.

PMID: 39768605 PMC: 11676722. DOI: 10.3390/jcm13247682.


Sex Disparities in Bladder Cancer Diagnosis and Treatment.

Pignot G, Barthelemy P, Borchiellini D Cancers (Basel). 2024; 16(23).

PMID: 39682286 PMC: 11640134. DOI: 10.3390/cancers16234100.


Single-cell RNA sequencing analysis reveals the dynamic changes in the tumor microenvironment during NMIBC recurrence.

Chen Z, Zhang T, Li W, Hu J, Ou Y, Ye F Apoptosis. 2024; 30(1-2):282-296.

PMID: 39633115 DOI: 10.1007/s10495-024-02044-2.


Real-world outcomes for high-risk non-muscle-invasive bladder cancer: screened patients for the BRAVO trial.

Conroy S, Jubber I, Noon A, Rosario D, Griffin J, Morgan S BJU Int. 2024; 135(2):329-338.

PMID: 39324506 PMC: 11745995. DOI: 10.1111/bju.16516.